---
title: 'Magrolimab plus azacitidine vs physician''s choice for untreated TP53-mutated
  acute myeloid leukemia: the ENHANCE-2 study'
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009500/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250227170931&v=2.18.0.post9+e462414
source: Blood
description: Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely
  poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2
  trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine (Magro/Aza)
  for previously untreated TP53-mutated AML. Patients determined inappropriate for
  intensive therapy were randomized to receive Magro/Aza or venetoclax plus azacitidine
  (Ven/Aza); those appropriate for intensive therapy were randomized to ...
disable_comments: true
---
Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine (Magro/Aza) for previously untreated TP53-mutated AML. Patients determined inappropriate for intensive therapy were randomized to receive Magro/Aza or venetoclax plus azacitidine (Ven/Aza); those appropriate for intensive therapy were randomized to ...